TARS
Tarsus Pharmaceuticals, Inc.78.28
-2.20-2.73%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
FY Q4 '25
Reaffirms guidance; adds prescribing depth.
Q&A largely reaffirmed prepared remarks on XDEMVY's $670M-$700M 2026 guidance, detailing Q1 flatness from deductibles, weather, and holidays before sequential ramps. Management clarified $2B peak sales as U.S.-only, eyeing ex-U.S. at ~10% long-term. Prescribing deepened across optometry (2/3) and ophthalmology: 40% of core target now weekly, daily writers up 20%. DTC at $80M draws positive ROI; no post-2026 OpEx jumps eyed. Analysts pressed seasonality and peaks—answers direct, confident. Momentum builds. Watch refill protocols and key account leaders.
Key Stats
Market Cap
3.32BP/E (TTM)
-Basic EPS (TTM)
-1.99Dividend Yield
0%Recent Filings
8-K
XDEMVY sales soar 150%
Tarsus Pharmaceuticals reported full-year 2025 XDEMVY net product sales of $451.4 million, up over 150% from 2024, with Q4 at $151.7 million. Cash swelled to $417.3 million; net loss narrowed to $66.4 million. Pipeline advances: Phase 2 TP-04 ocular rosacea trial started, TP-05 Lyme prevention in Q2 2026. XDEMVY sales exploded.
10-K
FY2025 results
Tarsus Pharmaceuticals posted FY2025 results for the year ended December 31, 2025, reflecting early commercialization of XDEMVY launched in August 2023, yet continued operating losses and negative cash flows amid pipeline investments. No quarterly revenue or profitability breakdowns disclosed in the 10-K. Clinical momentum built with positive Ersa and Rhea trial data in late 2024 and 2025, showing XDEMVY's statistically significant improvements in Meibomian Gland Disease metrics versus vehicle. Pipeline advances TP-04 for ocular rosacea and TP-05 for Lyme prophylaxis. Cash position supported by March 2025 public offering and 2024 credit facility. Reliance on single product sales heightens commercialization risks.
8-K
Tarsus adds Pyott to board
Tarsus Pharmaceuticals expanded its board to eight members, appointing David E.I. Pyott—ex-Allergan CEO who scaled the firm from $1B to over $7B in sales—as a Class III director on February 18, 2026. He joins as Commercial Committee Chair and Compensation and Nominating Committee member, receiving $540,000 in initial equity compensation. Pyott's eye care expertise bolsters XDEMVY scaling and pipeline push. No related transactions disclosed.
8-K
XDEMVY sales guidance soars
Tarsus Pharmaceuticals published its January 2026 corporate presentation under Item 7.01, projecting XDEMVY net sales at $440-$445M for 2025, up sharply from $180M in 2024, with peak potential beyond $1B. DTC campaigns boosted awareness 42% and prescriptions. Pipeline advances: Phase 2 ocular rosacea trial started December 2025; Lyme prevention Phase 2 planned 2026. Sales engine revs hard.
10-Q
Q3 FY2025 results
Tarsus Pharmaceuticals crushed Q3 with XDEMVY net product sales rocketing 147% y/y to $118.7M, while narrowing operating loss to $14.5M from $25.2M and net loss to $12.6M ($0.30/share) from $23.4M ($0.61/share)—EPS reconciles to 42.6M diluted shares. YTD sales hit $299.7M, up from $113.7M, yet SG&A swelled to support the ramp. Cash swelled to $112.7M plus $289.1M marketable securities, backed by $72.3M net debt under the 2024 Credit Facility (SOFR+6.75%, due 2029). Revenue relies on two customers for 77%. XDEMVY sales keep surging.
CLSD
Clearside Biomedical, Inc.
0.41+0.41
DRMA
Dermata Therapeutics, Inc.
2.32-0.16
KALA
KALA BIO, Inc.
0.56-0.05
KLRS
Kalaris Therapeutics, Inc.
8.66+0.16
LIANY
LianBio
0.09+0.00
NBY
NovaBay Pharmaceuticals, Inc.
3.16+0.45
PVCT
Provectus Biopharmaceuticals, I
0.06+0.00
SPRY
ARS Pharmaceuticals, Inc.
10.66+0.07
TVRD
Tvardi Therapeutics, Inc.
4.20-0.02
XERS
Xeris Biopharma Holdings, Inc.
7.10+0.05